8-K: IO Biotech Phase 3 Trial for Melanoma Treatment Continues After Positive Interim Review

IO Biotech's Phase 3 trial of IO102-IO103 in combination with KEYTRUDA for advanced melanoma will continue without modifications after a positive interim analysis by the Independent Data Monitoring Committee.

Summary

• IO Biotech announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of their Phase 3 trial for IO102-IO103 in combination with KEYTRUDA for advanced melanoma.
• The IDMC's decision was based on a per-protocol interim analysis of safety and efficacy data.
• No new safety signals were observed during the interim analysis.
• The primary endpoint of progression-free survival (PFS) is projected to be reached in the first half of 2025.
• The interim efficacy analysis did not meet the criteria to declare superiority of overall response rate (ORR) due to a high statistical bar.
• The trial is designed to preserve most of the statistical alpha for the primary endpoint of PFS.
• The PFS analysis will be conducted when 226 events (disease progression or death) have been reported.
• The trial has enrolled 407 patients and is powered at 89% to detect a 35% reduction in the risk of an event.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with the trial continuing without modifications and no new safety signals. However, the lack of ORR superiority in the interim analysis and the wait for PFS results temper the overall sentiment.

Positives

• The IDMC recommended the trial continue without modifications, indicating a positive assessment of the safety and efficacy data.
• The trial is powered at 89% to detect a 35% reduction in the risk of an event, suggesting a high likelihood of achieving statistical significance for the primary endpoint.
• The company remains optimistic about meeting the primary endpoint of PFS based on previous Phase 1/2 trial results.
• The trial has enrolled 407 patients across multiple countries, indicating strong interest and participation.
• The company has received breakthrough therapy designation from the FDA for IO102-IO103 in combination with pembrolizumab for the treatment of advanced melanoma.

Negatives

• The interim efficacy analysis did not meet the criteria to declare superiority of overall response rate (ORR), although this was expected due to the high statistical bar set for the interim analysis.
• The primary endpoint of progression-free survival (PFS) is not expected until the first half of 2025, meaning a significant wait for the final results.

Risks

• The trial's primary endpoint of progression-free survival (PFS) is not expected until the first half of 2025, which introduces uncertainty regarding the final outcome.
• The interim analysis did not show superiority in overall response rate (ORR), which could be a concern if the PFS results are not strong enough.
• The success of the trial depends on the occurrence of 226 events (disease progression or death), which could be influenced by various factors.
• The company's forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied.

Future Outlook

The company anticipates reaching the primary endpoint of progression-free survival (PFS) in the first half of 2025 and remains optimistic about the trial's outcome based on previous Phase 1/2 results. They are also enthusiastic about preliminary data from Phase 2 trials for other cancer types.

Management Comments

• Mai-Britt Zocca, PhD, President and CEO of IO Biotech, stated that the company remains optimistic about meeting the primary endpoint of PFS based on the 25.5 months median PFS observed in the Phase 1/2 trial.
• Igor Puzanov, MD, MSCI, FACP, commented that the treatment has the potential to transform the treatment paradigm for advanced melanoma.
• Jessica Hassel, MD, expressed confidence that IO102-IO103 in combination with pembrolizumab could offer new hope for treating patients with advanced melanoma.
• Dr. Zocca also mentioned the encouraging preliminary data from Phase 2 trials for non-small cell lung cancer and squamous cell carcinoma of the head and neck.

Industry Context

The announcement is relevant to the broader trend of developing novel immunotherapies for cancer treatment, particularly in melanoma. The combination of a therapeutic cancer vaccine with an anti-PD-1 therapy like KEYTRUDA is a strategy being explored by multiple companies in the field.

Comparison to Industry Standards

• The document mentions that none of the approved immunotherapeutic combinations for the treatment of advanced melanoma demonstrated statistical significance in ORR in large Phase 3 trials, but these trials achieved statistical significance on PFS.
• This suggests that IO Biotech's approach is aligned with industry trends, where PFS is often the primary endpoint for these types of trials.
• The company's previous Phase 1/2 trial showed a 25.5 months median PFS, which is a competitive result compared to other treatments in the field.
• Companies like Bristol Myers Squibb (Opdivo + Yervoy) and Merck (Keytruda) have established benchmarks in melanoma treatment, and IO Biotech is aiming to demonstrate comparable or superior results.

Stakeholder Impact

• Shareholders will be interested in the trial's progress and the potential for a successful outcome.
• Patients with advanced melanoma may benefit from this new treatment option if the trial is successful.
• Employees of IO Biotech are likely to be motivated by the positive interim results.
• Merck, as a collaborator, has a vested interest in the trial's success.

Next Steps

• The trial will continue as planned, with the primary endpoint of progression-free survival (PFS) expected in the first half of 2025.
• The company will continue to monitor the safety and efficacy data.
• Data from the SCCHN cohort has been accepted for poster presentation at the ESMO congress.
• Data from the NSCLC cohort has been accepted to another medical meeting in the fall.

Key Dates

Keywords

IO Biotech, IO102-IO103, KEYTRUDA, pembrolizumab, melanoma, cancer vaccine, Phase 3 trial, progression-free survival, IDMC, immunotherapy